Multidisciplinary evaluations of patients with non-small cell lung cancer (NSCLC) should include radiation oncologists, because radiation therapy (RT) has a potential role in all stages of NSCLC.
New targeted therapy and immunotherapy regimens are frequently approved and added to the NCCN Guidelines® Non-Small Cell Lung Cancer. Newer testing methods are being developed for patients who are not medically fit for invasive testing. Oncologists should be familiar with the current biomarker testing recommendations to improve outcomes for their patients with metastatic NSCLC.
The treatment landscape for lung cancer, particularly non-small cell lung cancer, is constantly evolving, especially with the emergence of new biomarker testing, advances in radiation techniques, and the availability of new systemic therapies.
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy.
The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens.
Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.
Immunotherapy recommendations for patients with non-small cell lung cancer (NSCLC) are rapidly changing, and health care providers need to be aware of the most current recommendations in the NCCN Guidelines to improve outcomes for their patients.
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation therapy.
Facebook
X
LinkedIn
Forward
